Scrip Pharmaceuticals profiles Forendo Pharma

Forendo Pharma CEO, Risto Lammintausta, was interviewed by Scrip Pharmaceuticals for an Emerging Company Profile section of the publication: “Forendo Pharma: Tackling The Endometriosis Challenge”.

Get pdf version of the Scrip article by clicking here

SCRIP is a leading source of news and strategic analysis for the global pharmaceutical industry, with over 14,000 registered users from pharmaceutical and biotech companies worldwide.

The article covers the importance of early intervention and future diagnostic tools for endometriosis, the new concept of intracrinology as well as the unique benefits of Forendo’s HSD17B1 enzyme inhibitor against the unmet needs in endometriosis therapy today.